BOSTON, MABrigham and Women's Hospital (BWH) researchers have created a vaccine that is more potent than traditional vaccines available today. The glycoconjugate vaccine prototype is 100 times more effective than traditional glycoconjugate vaccines. Their work is published in the December 2011 issue of Nature Medicine.
A glycoconjugate vaccine is comprised of covalently bound carbohydrate and protein molecules, and is the standard design for many vaccines used to protect against common diseases such as pneumonia and meningitis.
Researchers designed the vaccine prototype after discovering that immune cells, called T-cells, can recognize a vaccine's carbohydrates, and from that recognition elicit an immune response. This discovery challenges popular assumptions that immune cells only recognize the protein portion of glycoconjugate vaccines.
Proof that T-cells recognize carbohydrates came when researchers immunized mice with different types of glycoconjugate vaccines against the bacteria, group B Streptococcus. One group was immunized with vaccines containing different proteins. Another group was immunized with vaccines with the same proteins. For both groups, the carbohydrate chain in the vaccines was the same.
Researchers saw that mice given the vaccines with different proteins had just as good an immune response as those given vaccines with the same proteinsthe variability in proteins did not change immune response. This told researchers that T-cells were recognizing carbohydrates to generate a consistent immune response. They further investigated the mechanisms responsible for how carbohydrate-containing glycoconjugate vaccines activate protective immunity to a bacterial infection.
"One thing that is tremendously novel here is that we were able to find T-cells within a mouse after immunization with a glycoconjugate [vaccine] that just recognized carbohydrates," said Dennis L. Kasper, MD, director of
|Contact: Marjorie Montemayor-Quellenberg|
Brigham and Women's Hospital